B ecause cigarette smoking is a potent risk factor for coronary artery disease, over a quarter of patients presenting for percutaneous coronary intervention (PCI) are smoking at the time of treatment. 1, 2 In other diseases, such as vascular surgery, the benefits of treatment are severely undermined if patients continue to smoke. 3, 4 Although available data suggest a survival benefit from smoking cessation after PCI, 2 understanding the association of smoking cessation with patients' health status (their symptoms, function, and quality of life [QOL]) is of great importance because this is the primary benefit of PCI in most clinical settings, except reperfusion at the time of an ST-segment-elevation myocardial infarction. 5 Several previous studies have suggested that smokers who stop smoking after PCI have better health status outcomes than those who continue to smoke, 6,7 but these were conducted before the recent era of drug-eluting stents, aggressive secondary prevention, and the emphasis on smoking cessation as a performance measure of quality. 8
quit smoking after their procedure with those who were not smoking before PCI.
Methods

Participants
To examine the health status outcomes after PCI as a function of smoking status, we leveraged the Outcomes of PCI Study (OPS)/ Personalized Risk Information Services Manager (PRISM) study, a 10-center prospective PCI registry developed to test the benefits of a novel informed consent process using individualized, evidence-based estimates of procedural risks. 9 Consecutive patients undergoing PCI were enrolled and those who completed 1-year clinical follow-up with the disease-specific health Seattle Angina Questionnaire (SAQ) and generic EuroQol 5 dimensions (EQ-5D) were included in the present analysis. Each patient underwent a detailed, independent chart abstraction by trained study coordinators to collect demographic, comorbidity, and disease severity information (Table 1) . Patients also completed an interview at the time of their procedure and at 1, 6, and 12 months to qualify their health status and smoking. Institutional Review Board approval was obtained from all participating sites, and all patients provided written informed consent for baseline and follow-up assessments.
Smoking Status Categorization
Smoking status was assessed by self-report using the recommendations of the Society for Nicotine Research and Tobacco to characterize smoking habits. 10, 11 Patients were asked "Which of the following best describes your cigarette smoking status? (1) Have never smoked, not even a puff; (2) have smoked in the past but <100 cigarettes total; (3) stopped smoking >1 year ago; (4) stopped smoking between 1 month and 1 year ago; and (5) have smoked (even a puff) in the past 30 days." We categorized smoking status based on baseline and 1-year responses. At baseline, responses 1 and 2 were categorized as never smokers. Responses 3 and 4 were categorized as past smokers (quit before PCI), and response 5 was categorized as current smokers. At 1 year, we reclassified current smokers into 2 groups, including quitters and persistent smokers, based on patient's self-reported smoking status at 1 year. Table I in the Data Supplement provides more extensive details on our categorization.
Outcome Measures
Although health status assessments were collected throughout the year of follow-up, the benefits of smoking cessation often take months to years to emerge. [12] [13] [14] We, thus, focused on patients' health status at 1 year after PCI to maximize the length of follow-up. Both disease-specific and generic health-related QOL (HRQOL) questionnaires were assessed, as described below. HRQOL was defined as the functional effect of an illness and its consequent therapy on a patient, as perceived by the patient. 15
Disease-Specific Health Status: SAQ
The SAQ is a disease-specific health status measure for patients with coronary artery disease that has previously been demonstrated to be valid, reliable, and sensitive to clinical changes. [16] [17] [18] [19] It is also associated with subsequent survival, rehospitalization rates, and costs. [20] [21] [22] For this study, we focused on the SAQ angina frequency, physical limitation, and QOL domains as they were deemed, a priori, to be most relevant to the current analysis. Each domain score is transformed to a 0 to 100 scale, with higher scores indicating fewer symptoms, better functioning or greater QOL. A score of 100 indicates no angina, no physical limitations because of angina, and no effect of angina on patients' perceived QOL. 16, 18, 22 
Generic Health Status: EQ-5D Questionnaire
We also used EQ-5D, developed by the EuroQol group, to qualify patients' overall health status. 23, 24 There is a 20-cm visual analog scale (VAS) with anchors of best imaginable health state (a score of 100) and worst imaginable health state (a score of 0). 24 The EQ-5D VAS represents patients' overall views of their QOL and has been previously validated for patients with acute coronary syndrome. 25, 26 
Statistical Analysis
As described above, patients were initially categorized into 4 groups based on their smoking status: never smokers, past smokers, quitters, and persistent smokers. Baseline characteristics of patients across smoking categories were compared using χ 2 tests for categorical variables and ANOVA for continuous variables. To adjust for observed differences in 1-year health status, we used multivariable linear models to adjust for potential confounders at the time of PCI. Specifically, we adjusted for baseline health status in each model that included patients' baseline score for the domain of interest. In addition, we adjusted for clinically relevant and statistically significant factors that differed between smoking groups. These included demographic factors (age, sex, race, insurance status, marital status, and education level), medical history (hypertension, dyslipidemia, diabetes mellitus, chronic lung disease, previous myocardial infarction, previous PCI, previous coronary artery bypass grafting, previous heart failure, atrial fibrillation/ flutter, peripheral artery disease, cerebrovascular accident/transient ischemic attack, and chronic kidney disease), disease severity (cardiogenic shock and left ventricular ejection fraction, <40%), angiographic and procedural characteristics (indication for PCI, use of drug-eluting stents, number of diseased/treated vessels, and number of residual untreated vessels), treatment received (dual-antiplatelet therapy and number of cardiac medications at discharge), and postprocedure bleeding. Statistical significance was defined as a 2-sided P value of ≤0.05. All analyses were conducted using SAS version 9.3 (SAS Institute Inc, Cary, NC).
Results
Baseline Patient Characteristics
Of the 3299 patients who completed the baseline HRQOL questionnaires at 10 hospitals, 15 patients were missing baseline smoking status and 1 patient died before discharge. In
WHAT IS KNOWN
• Over a quarter of patients presenting for percutaneous coronary intervention smoke at the time of treatment.
• Although the mortality benefits of smoking cessation have been well established, the association of quitting smoking on health status outcomes, including patient symptoms, function, and quality of life, has been rarely studied. • Among the two thirds of smokers who continued to smoke after percutaneous coronary intervention, their angina was significantly worse at 1 year than patients who smoked at the time of percutaneous coronary intervention but quit after treatment.
WHAT THE STUDY ADDS
• These health status benefits of smoking cessation were observed within only 1 year of percutaneous coronary intervention. addition, we excluded 518 patients without 1-year smoking status, leaving 2765 (83.8%) for analysis ( Figure 1 ). The differences in baseline demographics (age, sex, race, and marital status) and clinical factors (diabetes mellitus, chronic kidney disease, previous myocardial infarction, and chronic heart failure) between included and excluded participants are described in Table II in the Data Supplement. At the time of the index PCI, 504 (18%) patients were current smokers, 1326 (48%) were past smokers, and 935 patients (34%) were nonsmokers. During the 1-year follow-up, 189 (37.5%) of the smokers quit and 315 (62.5%) persisted in smoking.
There were marked differences in baseline demographic and clinical characteristics according to smoking status (Table 1) . Persistent smokers and patients who quit smoking after PCI were, on average, 7 and 8 years younger than never smokers (57±9 and 59±9 versus 66±11 years old; P<0.001). Fewer patients who were past smokers were women. There were also significant differences in other demographic and clinical characteristics, including that patients who never smoked and who were past smokers were more likely to have graduated from high school, to be married, and to have a history of diabetes mellitus and chronic kidney disease than those who were smoking at baseline. Patients who smoked at the time of their PCI were more likely to have presented with an acute coronary syndrome. Table 2 presents the baseline and 1-year HRQOL of patients stratified by smoking status. At baseline, active smokers had significantly lower SAQ QOL and EQ-5D scores than past and nonsmokers. One year after PCI, patients who never smoked and previously smoked had higher scores in all HRQOL domains than patients who continued to smoke after PCI (Figure 2) . Quitters had health status scores that were either similar to nonsmokers or intermediate between nonsmokers and persistent smokers.
Association of Smoking With HRQOL Outcomes After PCI
Specifically, the 1-year SAQ angina frequency scores of persistent smokers were significantly lower than those who never smoked, were past smokers, and who quit after their PCI (90.4±17.5 versus 94.6±13.7, 94.1±15.3, 94.3±13.3, respectively). The proportion of patients reporting any angina at 1 year (SAQ angina frequency score, <100) was significantly higher among persistent smoker when compared with the other groups (30.5% versus 18.6% for never smokers, 18.2% for past smokers, and 21.2% for quitters). SAQ physical limitation (92.7±17.8 versus 96.1±11.6 for never smokers, 95.8±12.4 for past smokers, and 93.0±16.7 for quitters) and SAQ QOL scores (73.0±23.9 versus 81.6±17.2 for never smokers, 82.0±18.7 for past smokers, and 76.5±21.3 for quitters) were also significantly lower for patients who continued to smoke than other patients, as were these patients' EQ-5D VAS scores at 12 months (68.0±20.9 versus 77.2±17.3 for never smokers, 75.2±18.4 for past smokers, and 72.5±18.9 for quitters). Figure 3 shows the fully adjusted differences in HRQOL outcomes according to smoking status, with never smokers as the reference group. Persistent smokers were significantly worse in all aspects of HRQOL domains when compared with never smokers. In the multivariable adjusted model, patients who persistently smoked reported significantly lower SAQ angina frequency, physical limitation, QOL, and EQ-5D VAS scores when compared with never smokers at 1-year follow-up. Past smokers had similar health status scores as those who never smoked. Importantly, among those who smoked at the time of PCI, quitters had significantly better angina control (mean difference, 2.73; 95% confidence interval, 0.13-5.33) than persistent smokers (Figure 3 ). Moreover, their QOL scores, both SAQ and EQ-5D VAS, trended toward being higher than persistent smokers at 1 year after their PCI (SAQ QOL mean difference, 1.97; 95% confidence interval, −1.24 to 5.18 and EQ-5D VAS mean difference, 2.45; 95% confidence interval, −0.58 to 5.49).
Adjusted Comparison of HRQOL Outcomes According to Smoking Status
Discussion
Although smoking rates have continued to decline over time in the United States, those who smoke at the time of PCI are strongly urged to quit as a key component of secondary prevention. In this study, the largest observational study to date to evaluate the association of smoking cessation with health status outcomes, we found that persistent smokers had significantly worse HRQOL when compared with never smokers, but quitters did not. Among 504 patients who were smoking at the time of PCI, those who continued to smoke had significantly more angina and a trend toward poorer diseasespecific and generic QOL than those who quit.
These findings support and extend previous observational studies demonstrating improved health status after PCI among those who stopped smoking. For example, Haddock et al 27 investigated the effect of smoking status at the time of PCI in 271 consecutive patients and found that smokers have worse Short Form-12 physical component scores, more angina, and poorer disease-specific QOL, as assessed by the SAQ 12 months after their procedure. Our work extends this observation by stratifying those who smoked at the time of PCI into those who quit and those who continued smoking and found much worse outcomes in the latter, which confirms the study of Taira et al 6 in 1423 patients. Although the exact pathophysiological mechanism underlying the association between smoking status and angina after PCI is unknown, it is congruent with basic science studies that demonstrate correlations between smoking and vascular reactivity, 28 oxidative stress, 29, 30 endothelial damage, 31 endothelial vasomotor dysfunction, 32 platelet aggregation, 33, 34 and adhesion. 35 Regardless of the exact mechanism and we acknowledge that no causal relationship has been established, the findings from this and previous studies can be shared with PCI patients who smoke to further motivate them to quit.
The benefits of smoking cessation have been clearly established. Patients with cardiovascular disease, including those who undergo PCI, will benefit from smoking cessation more than the general population. 7 The higher likelihood of presenting with an acute coronary syndrome among patients who smoked at the time of PCI in our study suggests that they have more rupture-prone unstable plaques when compared with never smokers or past-smokers, as previously described. [36] [37] [38] Although the reduction of cardiac event rates among the general population varies across studies, 39, 40 the risks of adverse cardiac events with cigarette smoking diminish relatively early after smoking cessation in patients with established coronary artery disease and these benefits continue to increase over time after quitting. 41 In a meta-analysis of 20 cohort studies, including 12 603 smoking patients with ischemic heart disease, cessation of smoking after acute myocardial infarction or cardiac surgery dramatically reduced mortality (relative risk, 0.64; 95% confidence interval, 0.58-0.71). 7 In our study, 50% to 70% of patients, across smoking categories, presented with an acute coronary syndrome, for whom substantial effort is often expended to encourage these smokers to quit. However, only a small proportion of patients (37.5%) actually quit smoking after their PCI in our cohort, underscoring the limited effectiveness of current smoking cessation efforts. In this context, healthcare professionals need to further motivate patients to quit smoking. The findings from this study may support these efforts as we have shown that persistent smoking is associated with worse health status outcomes after PCI, the primary purpose of the procedure in stable coronary disease. Although previous clinical trials of aggressive smoking cessation strategies, including nicotine replacement therapy for patients with coronary artery disease, proved to be safe and effective, 42 many clinicians have been reluctant to prescribe nicotine to patients with cardiovascular disease. 43 One potential reason why clinicians are not effectively treating smoking habits is that they have grown numb to the mortality benefits, and these data may further motivate them to use PCI as a teachable moment to support their patients in stopping smoking. 44 Although cessation of smoking rapidly reduces the risk of fatal cardiovascular events through several pathophysiologic mechanisms, 14, 34, 45, 46 there have been controversies how quickly and how much risk of adverse clinical outcomes will be affected by smoking cessation. Some authors have suggested that substantial improvements occur within 2 to 3 years after smoking cessation, 12, 14 whereas others estimate that risk of adverse outcomes does not fall to the level of nonsmokers even after 20 years. 47, 48 In our study, it took only 1 year to see that smoking cessation was associated with better health status outcomes.
Limitations
There are several potential limitations to this study that should be considered. First, there may have been misclassification of smoking status over time, as we did not use biological markers, such as cotinine levels, to verify smoking status. Such misclassification, however, would be expected to dilute the differences between groups, and our results may therefore be a conservative estimate of the true benefit of smoking cessation. Second, we could not distinguish differences in smoking intensity among persistent smokers and past smokers although the benefits of smoking cessation on cardiovascular outcomes might vary with the amount of cigarettes patients had smoked before their procedure. Third, unmeasured residual confounders might have contributed to differences in HRQOL scores at follow-up. Although we attempted to adjust for numerous clinical and socioeconomic factors, the possibility of residual unmeasured confounding remains. For example, we did not adjust for the quality of PCI, although we did not find significant differences in the number of diseased vessels or treated vessels between quitters and persistent smokers. Fourth, the sample size was relatively small, especially in quitters and persistent smokers. Although the lack of statistically significant differences in HRQOL outcomes between quitters and nonsmokers might have been limited by statistical power, we did have sufficient power to demonstrate significantly less angina in smokers who quit when compared with smokers who continued to smoke. In addition, given our modest sample size and the number of comparisons made, our data should be interpreted with caution and confirmed in future studies. Moreover, clinicians performing PCI have no control over whether patients were smoking before treatment but can influence their decision to stop smoking afterward. Being able to share with patients, the potential health status advantages of quitting might therefore be helpful in clinical practice. An additional limitation is that we were not able to report on benefits with respect to major adverse cardiac events over the year after PCI, as documented by others, 2, 7, 49 and this important complementary information would help support the angina relief that we found to be associated with quitting smoking. Finally, the follow-up period was only 1 year, precluding our ability to define longer-term benefits of smoking cessation.
Conclusions
Individuals who continue smoking after the PCI experienced significantly poorer HRQOL outcomes than patients who have never smoked. We also found that patients who quit smoking after PCI demonstrated significantly better angina control 1 year later when compared with persistent smokers. Whether sharing these additional insights with patients who smoke at the time of PCI would improve their success in quitting should be tested in future studies.
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